On 1 September the FDA posted warning letters to five online peptide sellers at once. Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations trading as Tex Peptides.
The action itself is unsurprising. What the agency accepted as evidence is the part worth reading.
Reading the NuScience letter, the claims cited are far milder than anyone would guess. Several are written in careful research language, describing rodent models and preclinical findings, exactly as a cautious seller would phrase them. The FDA cited them anyway.
What the FDA quoted as evidence
These are examples the agency gave as evidence that products were intended as drugs.
On tirzepatide, sold as "GLP-2 Tirz Peptide": that it has been extensively studied in rodent models, particularly rats, to explore its metabolic effects.
On survodutide: that preclinical studies in rodent models have demonstrated its efficacy in promoting weight loss and improving glycemic control.
On PT-141: that it has been widely examined in preclinical models to better understand melanocortin-mediated signalling pathways involved in sexual behaviour.
None of that reads like a claim to treat anybody. It reads like a mechanism description, hedged toward research, and that register is the one these sites use to stay on the right side of the line.
The agency's position is that describing what a compound does to the structure or function of the body establishes intended use, whatever frame it sits in. Our guide on what research use only actually means sets out that doctrine, and this is it applied to five real companies.
Why SS-31 is the strangest one on the list
Two of the letters cite SS-31. Peak Performance listed it alongside bacteriostatic water, retatrutide, semaglutide, PT-141 and tesamorelin. Peptide Partners listed it as "SS-31 (Elamipretide)," which is the FDA naming the approved drug in the same breath as the research-labelled version.
That matters, because elamipretide received FDA accelerated approval in September 2025 and sells as Forzinity for Barth syndrome. Our longevity roundup covers that approval in detail.
So a vendor was offering a research-labelled version of a compound the agency had approved eleven months earlier, for a different purpose, and without any of the manufacturing or evidence framework approval requires. That is a different situation from selling an analogue of semaglutide. There is now an approved version, made to a reviewed standard, and a vial from a website is not it.
Bacteriostatic water appears in at least three of the five letters, listed by Peptide Partners as "Reconstitution Solution (BAC)." Three letters carrying the same theory makes it a settled position.
Three details worth more than the letters
A claim on somebody else's website counted
One cited passage for semaglutide was not on the seller's own page. It was on PubChem, hyperlinked from the product listing, describing the mechanism of cardiovascular benefit and weight loss.
Linking to a third-party description was treated as part of the product's labelling.
Bacteriostatic water became a drug
The letter states it plainly. Offering reconstitution water for sale alongside injectable peptide products demonstrates an intended combined use, so the water is itself a drug.
Our guide on bacteriostatic water covers what the product is. What it did not anticipate is that selling it next to a vial is what converts it, in the agency's reading, from a laboratory supply into an unapproved drug.
A dose calculator was cited as evidence
The detail with the widest implications sits in a footnote, and a version of it appears in every letter in the sweep.
The labelling said "for laboratory, research, and analytical use." It also said "not intended for human or veterinary use." The agency notes that the seller nonetheless marketed bacteriostatic water alongside a peptide calculator. It describes that calculator as a resource providing the means to prepare an injectable drug for human administration.
A tool for working out reconstitution volumes, on a site that sells the vials, was treated as evidence that the vendor expects human injection.
Renaming did not help
The products were listed as "GLP-1 Sema Research Peptide," "GLP-2 Tirz Peptide" and "GLP-3 RT." Peptide Partners used "GLP-1 S," "GLP-2 T" and "GLP-3 Reta." Every letter names them in those terms and then treats them as semaglutide, tirzepatide and retatrutide throughout.
This is not new either. The December 2024 letter to Summit Research Peptides cites products sold as "Sema," "Reta" and "Tirz," and treats them the same way. The abbreviation has been failing for two years.
The 2024 letters add one thing the recent ones do not spell out. The agency reviewed the sellers' Facebook, Instagram and YouTube accounts as well, noting that they direct consumers to the website to purchase. Social channels were treated as part of the same commercial presentation.
Retatrutide is worth separating out. It is an investigational drug with no approval anywhere, and our coverage of its filing timeline explains where it sits. Selling it at all is a different proposition from selling an analogue of something approved.
Has the FDA done this before?
The trail goes back further than the coverage suggests.
In December 2024 the agency sent letters to Summit Research Peptides and to Prime Vitality trading as Prime Peptides. Summit was cited for semaglutide, retatrutide, cagrilintide, tirzepatide and mazdutide. Prime was cited for semaglutide and retatrutide. Both were reviewed the previous October, both from the same office at CDER, both on the same legal theory.
A further letter went to Pinnacle Professional Research trading as Pinnacle Peptides in December 2025, which we have not read at source.
So the August 2026 sweep is the third round in under two years. One or two letters at a time became five posted together, and the legal reasoning did not move.
That matters for anyone deciding what to make of it. A stated position is being applied more widely, which is a different thing from a new policy arriving without warning.
What does an FDA warning letter actually mean?
A formal statement of the agency's position, not a court finding. Recipients have fifteen business days to respond, and they can dispute the facts, correct conduct, or later receive a close-out letter.
It does name the consequences. Failure to address the violations may result in regulatory or legal action without further notice, including seizure and injunction.
The letter also explains why injectables draw particular attention. They go directly into the body, bypassing some of its key defences against toxins and microorganisms.
So the FDA has alleged, publicly and in detail, and the matter is not concluded.
Is it safe to keep buying from these vendors?
Seeing your own supplier named in a federal warning letter is unsettling. What the letters actually establish is narrower than it looks.
Nothing has been said about your vials. The letters concern approval status and marketing, and no product was tested. Nobody has found contamination, or underdosing, or anything else about what is in the bottle. If your vendor's testing was good before September, it is the same testing now.
Nothing has been recalled, and nothing has been shut down. A warning letter is a formal allegation with a response window, and orders continue to ship while that plays out.
So neither panic nor ignoring it is the right response. What the letters tell you is where the line now sits, and it is further over than most people assumed.
Research framing does not protect a seller
Careful language about rodent models was cited as evidence in this sweep. A site reading as more responsible than its competitors can still be non-compliant.
The disclaimer does less than it appears to
The letter quotes the not-for-human-use language and then explains why the surrounding presentation overrides it. Our legality guide covers why that phrase does less work than its prominence suggests.
The whole commercial presentation counts
Product copy, links, bundled water, calculators, and how the pieces sit together. Our guide on vetting a vendor is about assessing quality, and this is a reminder that a polished site is a commercial artefact rather than a compliance signal.
Supply may become unreliable
Of everything here, this is what will actually reach you. Companies under regulatory pressure change catalogues, restructure, or occasionally disappear. Our guide on what to do when a vendor vanishes covers the position if that happens to an order you have already paid for.
What do peptide vendors do after a warning letter?
Worth knowing, because you will watch it happen to sites you use.
The cheapest response is editorial. Product descriptions get stripped of mechanism language, research citations disappear, and the copy becomes so bare it says almost nothing. That answers the letter without changing what is in the vial.
Renaming is the second move, and this sweep demonstrates its limits. The products were already listed as "GLP-1 Sema," "GLP-2 Tirz" and "GLP-3 RT," and the letters name them as semaglutide, tirzepatide and retatrutide throughout.
Some restructure, moving the storefront offshore or behind a login. Some remove the compounds named in their letter and keep the rest.
And some do nothing, which is what the escalation language exists for.
For a buyer the practical signal is a site whose product pages suddenly go quiet. That is a vendor becoming more careful about its copy, which is a different thing from becoming more careful about its product.
What to watch
Response and close-out letters, which appear on the same FDA index and change the status of each case.
Whether escalation follows for any recipient, meaning seizure or injunction.
State action, which runs on a separate track. More than forty state attorneys general wrote to the FDA raising contamination and safety concerns, and pharmacy licensing and consumer protection enforcement both sit at state level. Our piece on the compounded semaglutide position covers how that patchwork works.
Whether the sweep continues. Five letters posted together signals a coordinated posture and not an isolated dispute, and the same reasoning applies to a great many sites.
Where this stops being useful
Whether any individual recipient has responded or corrected. The FDA index will show that; nothing here can.
What happens to any specific order you have placed.
Anything about compounding pharmacies, which is a separate regulatory track covered in our piece on the compounded semaglutide position.
Common questions
What did the FDA say these sellers did wrong?
Sold unapproved new drugs and misbranded products. The agency's position is that website content established the products were intended to affect the structure or function of the body, which makes them drugs regardless of a research-use label.
Were the claims outrageous?
No, and that is the striking part. Several cited passages describe rodent studies and mechanisms in careful research language. The agency treated those as evidence of intended use.
Why was bacteriostatic water included?
Because it was sold alongside injectable products. The letter states that selling them together demonstrates an intended combined use, which makes the water a drug.
Does this mean the products were contaminated?
No. The letters are about approval status and marketing, not about testing any product. An unapproved finding is a statement about the regulatory framework, not about what is in a particular vial.
Are these companies shut down?
No. A warning letter is a formal allegation with a fifteen business day response window, and it carries none of the force of a court order or a recall.
Does "not for human consumption" work?
The letter quotes exactly that language and explains why the surrounding presentation overrode it. It is one piece of evidence among many rather than a shield.
Will my order still arrive?
Nothing about a warning letter stops shipments directly. Whether a given vendor changes its site, its catalogue or its operations is up to them.
Is retatrutide different?
Yes. It is investigational with no approval anywhere, so there is no approved version to compare it to. That puts it in a weaker position than an analogue of a licensed drug.
Sources
FDA. Warning Letter to NuScience Peptides LLC, MARCS-CMS 733652, 24 August 2026. Regulatory document, read at source. Issued by the Center for Drug Evaluation and Research, Office of Unapproved Drugs and Labeling Compliance, and signed by Tina Smith. Posted 1 September 2026. Identifies nine products as unapproved new drugs under section 505(a) of the FD&C Act. All quoted marketing language in this article is taken from the letter's own citations. Fifteen business day response window; seizure and injunction named as possible consequences.
FDA warning letters to Peak Performance Peptides (MARCS-CMS 735127) and Peptide Partners LLC (MARCS-CMS 735063), both 24 August 2026. Regulatory documents. Both followed reviews of the sellers' websites in July 2026 and identify comparable product lists, including SS-31 (Elamipretide) and "Reconstitution Solution (BAC)."
FDA. Warning Letters index. The index lists the peptide company letters with an issue date of 24 August 2026 and a posting date of 1 September 2026. It is also where response and close-out letters appear, which is the source to check before treating any status described here as current.
FDA. Warning Letter to Summit Research Peptides, MARCS-CMS 695607 and Warning Letter to Prime Vitality Inc dba Prime Peptides, MARCS-CMS 695156, both 10 December 2024. Regulatory documents. Both letters record that the agency also reviewed the sellers' social media accounts, and that those accounts direct consumers to the websites to purchase. Both cite sections 505(a) and 301(d) of the FD&C Act. A further letter to Pinnacle Professional Research dba Pinnacle Peptides (719337, December 2025) is reported in secondary sources and has not been read at source.
Warning letters to Royal Peptides and TXP Innovations, 24 August 2026. Issued the same day, reported across secondary sources with overlapping product lists including retatrutide, semaglutide, SS-31, PT-141 and tesamorelin.